Status: Recruiting
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
This study is a phase I clinical trial of multi-center, open label, dose increase and dose expansion. It aims to evaluate the safety, tolerance, PK characteristics, immunogenicity and initial efficacy of personalized new antigen mRNA vaccine RGL-270 (hereinafter referred to as RGL-270) alone and combined with adebelizumab in patients with high risk of recurrence of malignant solid tumors after radical treatment.
Participants needed: 198
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Xian-Jun YuUpdated: Jan 16, 2026Locations: 1
Eligibility criteria
Subjects should understand and abide by the relevant research procedures, and vo... [+8]
Pre-screening period [+28]